The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

PET-CT scans combine structural and functional imaging to detect diseases early. This technology improves diagnosis accuracy ...

Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round.

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

Skin health experts debunk collagen myths, like whether or not collagen supplements really work, and all the ways you can ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures ...

Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms.

Actithera, a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs), today announced the close of an oversubscribed $75.5 ...

This new article publication from Acta Pharmaceutica Sinica B, discusses a high clinically translatable strategy to anti-aging using hyaluronic acid and silk fibroin co-crosslinked hydrogels as dermal ...

This study reveals that neutrophil extracellular traps (NETs) drive macrophage-derived chemokine production (CXCL9/10/11) to promote CD8+ T cell ...